#CIPLA Pattern continues
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
CIPLA
655
-5.55 (-0.84%)
Updated 03:29 05/06 IST
CIPLA Buy or Sell - FrontPage Forums
3 Users have submitted 3 trade ideas of Rs. 1,350,227.03 for CIPLA
Disclaimer100% Bullish
0% Bearish
CIPLA Ratings
Long term CIPLA rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3.8/5 (16 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?
CIPLA Share Price Discussion
B
Reputation: 32 • Today 2:20 AM
Bulls vs Bears in CIPLA#CIPLA There's a deviation in the channel afte...
Like
Reply
Reputation: 3,179 • Today 7:48 AM
Monsoon to bring relief amid COVID-19 pain; 9 stocks that could benefit
Experts point out that the rabi season ended largely on expected lines and at present, it appears the Kharif crop is unlikely to be affected and may see a normal season.
Experts point out that the rabi season ended largely on expected lines and at present, it appears the Kharif crop is unlikely to be affected and may see a normal season.
Moneycontrol
Like
Reply
Reputation: 3,179 • Today 4:51 AM
Share market update: 29 stocks hit 52-week highs on NSE
Benchmark NSE Nifty index was trading 43.80 points up at 10072.90.
Benchmark NSE Nifty index was trading 43.80 points up at 10072.90.
The Economic Times
1
Reply
B
Reputation: 32 • Yesterday 11:41 AM
Bulls vs Bears in CIPLA#CIPLA Pattern to watch
#CIPLA There's a deviation in the channel after a minor breakdown.
Like
Reply
Reputation: 3,179 • Yesterday 5:51 AM
Share market update: Pharma shares up; Lupin rises over 2%
The Nifty Pharma index was trading 1.11 per cent up at 9973.95.
The Nifty Pharma index was trading 1.11 per cent up at 9973.95.
The Economic Times
Like
Reply
Reputation: 3,179 • Yesterday 4:41 AM
Share market update: 20 stocks hit 52-week highs on NSE
The BSE Sensex was trading 52.72 points down at 34056.82.
The BSE Sensex was trading 52.72 points down at 34056.82.
The Economic Times
Like
Reply
Reputation: 3,179 • Yesterday 2:01 AM
Indian licensees free to price Remdesivir: Gilead
US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country.
US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country.
The Economic Times
Like
Reply
Reputation: 3,179 • Jun 3 5:51 AM
Share market update: Pharma shares climb; Dr Reddy's Labs gains 2%
The Nifty Pharma index was trading 0.76 per cent up at 9908.5.
The Nifty Pharma index was trading 0.76 per cent up at 9908.5.
The Economic Times
Like
Reply
Reputation: 5,620 • Jun 2 2:20 AM
Our Darling CPR-ORB Performance:
#MUTHOOTHFIN NOT TRIGGER
SELL #HINDUNILIVER from 2102.60 TO LOW MADE 2101 NO MOVEMENT
SELL #BHARATFROG from 335.30 TO 332
BUY #DMART ...
Read more...
26
Reply (13)
Latest replies
@sushilkumar-SyuqvBbsL I'm telling because I know he wouldn't reply
@yash-rkwVuRG2I bro does cpr narrow range breakouts is working well it's profitable???? Please reply
@akashnv half of them work (1.5 RRR) remaining half either hit STL or don't breakout
@yash-rkwVuRG2I end of d day hum profit mein hi rehte h......backtest kar lo...... Isliye deta hu jisse aapko confidence aa sake
Yes. That's the logic, not all trades are profitable. You have to accept that and take reasonably assessed technically sound calls.
Harry also has some SRM strategy too to manage trades to remain profitable. I too have my own
Reputation: 442,155 • Jun 2 4:38 AM
DECENT PROFITS in CIPLANew trade: Sell CIPLA JUN20 FUT, CMP@646.7, Ent...
646.05
Like
Reply
Reputation: 6,068 • Jun 2 3:44 AM
BUY CIPLA 643.9 TARGET 649.5-656-662.5 STOPLOSS 640.15
2 nd target done - happy trading
profit rs. 12 per share
Like
Reply
Reputation: 3,179 • Jun 1 4:33 AM
Gilead gets conditional approval from India regulator to market remdesivir for COVID-19
The conditional marketing authorisation for remdesivir was granted under the accelerated review process considering the emergency situation and unmet medical needs
The conditional marketing authorisation for remdesivir was granted under the accelerated review process considering the emergency situation and unmet medical needs
Moneycontrol
Like
Reply
Reputation: 3,179 • Jun 1 4:33 AM
COVID-19 crisis | Remdesivir manufacturers may be allowed to sell only to government for now: Report
Gilead Sciences' experimental drug remdesivir has been found to aid recovery of COVID-19 patients.
Gilead Sciences' experimental drug remdesivir has been found to aid recovery of COVID-19 patients.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
CIPLA Share Price - Technicals
- NewsBotToday 7:48 AMMonsoon to bring relief amid COVID-19 pain; 9 stocks that could benefitMoneycontrolNewsBotToday 4:51 AMShare market update: 29 stocks hit 52-week highs on NSEThe Economic TimesNewsBotYesterday 2:01 AMIndian licensees free to price Remdesivir: GileadThe Economic TimesNewsBotJun 3 5:51 AMShare market update: Pharma shares climb; Dr Reddy's Labs gains 2%The Economic TimesNewsBotJun 1 4:33 AMGilead gets conditional approval from India regulator to market remdesivir for COVID-19MoneycontrolNewsBotJun 1 4:33 AMCOVID-19 crisis | Remdesivir manufacturers may be allowed to sell only to government for now: ReportMoneycontrolNewsBotMay 28 8:48 AM
Buy Cipla target of Rs 738: Anand RathiMoneycontrolNewsBotMay 26 6:53 AM
F&O expiry to keep market volatile; 5 stocks where experts see 8-16% upsideMoneycontrolNewsBotMay 21 3:03 AM
Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-YMoneycontrolNewsBotMay 21 2:23 AM
Looking for momentum plays? Top 4 stocks which could give over 15% returns in 1-3 monthsMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.